Drug Trial Radar · NCT05823012
Study of XP-8121 For the Treatment of Adult Subjects With Hypothyroidism
Last checked: Nov 20, 2026Latest source record: Jul 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
46
Actual
Start
May 15, 2023
Primary completion
Feb 22, 2024
Study completion Feb 22, 2024
Sponsor
- Lead sponsor
- Xeris PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Apr 21, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a non-randomized, open-label, single arm, self-controlled study of XP-8121 (levothyroxine sodium) to determine a target dose conversion factor from stably dosed oral levothyroxine to XP-8121 (levothyroxine sodium) in patients with hypothyroidism and to assess the safety and tolerability of XP-8121(levothyroxine sodium) after once weekly subcutaneous injections. This study includes the following periods: Screening, Titration Period, and Maintenance Period. The study will conclude with an End of Maintenance Visit or Early Termination (ET) Visit.
Conditions
- Hypothyroidism
Interventions
levothyroxine sodiumDrug
Levothyroxine sodium 10 mg/mL
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose Conversion FactorTime frame: Day 29 of the Maintenance Period
- Tolerability Assessment: Modified Draize Scale - ErythemaTime frame: Week 1 Dosing in Titration Period through Day 22 Dosing in Maintenance Period
- Tolerability Assessment: Modified Draize Scale - EdemaTime frame: Week 1 Dosing in Titration Period through Day 22 Dosing in Maintenance Period
- Tolerability Assessments: Injection Site Discomfort EvaluationTime frame: Week 1 dosing in the Titration Period through Day 22 dosing in the Maintenance Period
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
ProSciento, Inc.
Chula Vista, California
Catalina Research Institute, L.L.C.
Montclair, California
Panax Clinical Research, LLC
Miami Lakes, Florida
American Research Corporation
San Antonio, Texas
Mt. Olympus Medical Research, LLC
Sugar Land, Texas
Rainier Clinical Research Center
Renton, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.